Gene Therapy in Human Cancer: Report of Human Clinical Trials

References

• Rosenberg S A. Gene therapy for cancer. JAMA 1992; 268: 2416–2419
   PubMed Web of Science ®Google Scholar
• Blau H M, Springer M L. Gene therapy-a novel form of drug delivery. N Engl J Med 1995; 333: 1204–1207
   PubMed Web of Science ®Google Scholar
• Brenner M K. Gene transfer and the treatment of childhood cancer. Cancer Invest 1998; 16: 269–278
   PubMed Web of Science ®Google Scholar
• Jolly D. Viral vector systems for gene therapy. Cancer Gene Ther 1994; 1: 51–64
   PubMed Web of Science ®Google Scholar
• Culver K M. Gene therapy, a primer for physicians. Mary Ann Liebert, Inc, New York 1996
   Google Scholar
• Roth J. A., Cristiano R J. Gene therapy for cancer: what have we done and where are we going?. JNCI 1997; 89: 21–39
   PubMed Web of Science ®Google Scholar
• Dranoff G. Cancer gene therapy connecting basic research with clinical inquiry. J Clin Oncol 1998; 16: 2548–2556
   PubMed Web of Science ®Google Scholar
• , http://www.nih.gov/od/orda/protocol.htm
   Google Scholar
• Anderson W F. The ADA human gene therapy clinical protocol. Hum Gene Ther 1990; 1: 327–362
   PubMed Web of Science ®Google Scholar
• Brenner M K, Rill D R, Moen R C, et al. Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85–86
   PubMed Web of Science ®Google Scholar
• Brenner M K, Rill D R, Holladay M S, et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 1993; 342: 1134–1137
   PubMed Web of Science ®Google Scholar
• Miller A D. Retroviral vectors. Curr Topics Microbiol Immunol 1992; 158: 1–24
   PubMed Web of Science ®Google Scholar
• Wilson J M. Adenoviruses as gene delivery vehicles. N Engl J Med 1996; 334: 1185–1187
   PubMed Web of Science ®Google Scholar
• Engelhardt J F, Yang Y, Stratford-Perricaudet L D, et al. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nat Genet 1993; 4: 27–34
   PubMed Web of Science ®Google Scholar
• La Leal G., Salle G, Robert J J, Berrard S, et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 1993; 259: 988–990
   PubMed Web of Science ®Google Scholar
• Nabel G J, Nabel E G, Yang Z Y, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 11307–11311
   PubMed Web of Science ®Google Scholar
• Gao X., Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 1991; 179: 280–285
   PubMed Web of Science ®Google Scholar
• Trubetskoy V S, Torchilin V P, Kennel S J, et al. Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly-L-lysine antibody conjugate in mouse lung endothelial cells. Biochim Biophys Acta 1992; 1131: 311–313
   PubMed Web of Science ®Google Scholar
• Jones D. V, Jr. Liposomes in nucleic acid transfection, in vitro and in vivo studies. Applications for Liposomes in Human Malignancy: Current Status and Future Directions, S Sugarman, R Perez-Soler. RG Landes Company, Austin 1995; 153–172
   Google Scholar
• Askari F K, McDonnell W M. Antisense-oligonucleotide gene therapy. N Engl J Med 1996; 334: 316–318
   PubMed Web of Science ®Google Scholar
• Cheng L, Ziegelhoffer P. R., Yang N S. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA 1993; 90: 4455–4459
   PubMed Web of Science ®Google Scholar
• Nicolet C M, Burkholder J K, Gan J, et al. Expression of a tumorreactive antibody-interleukin 2 fusion protein after in vivo particle-mediated gene delivery. Cancer Gene Ther 1995; 2: 161–170
   PubMed Web of Science ®Google Scholar
• NaldiniBlomer L., Gallay U. P., et al. In vivo gene delivery and stable transduction of non dividing by a lentiviral vector. Science 1996; 272: 263–266
   PubMed Web of Science ®Google Scholar
• Donahue R E, Kessler S W, Bodine D, et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 1992; 176: 1125–1135
   PubMed Web of Science ®Google Scholar
• Vanin E., Kaloss F. M., Broscius C, et al. Characterization of repication-competent retroviruses from nonhuman primates with virusinduced T-cell lymphomas and observations regarding the mechanism of oncogenesis. J Virol 1994; 68: 4241–4250
   PubMed Web of Science ®Google Scholar
• Purcell D F, Broscius C M, Vanin E F, et al. An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer. J Virol 1996; 70: 887–897
   PubMed Web of Science ®Google Scholar
• Jones N, Shenk T. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell 1979; 17: 683–689
   PubMed Web of Science ®Google Scholar
• Bett A., Haddara W., Prevec L, et al. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802–8806
   PubMed Web of Science ®Google Scholar
• Isner J M, Walsh K, Symes J, et al. Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Hum Gen Ther 1996; 20: 959–988
   Google Scholar
• Hollstein M, Vogelstein D., Sidrensky B., et al. p53 mutations in human cancer. Science 1991; 253: 49–53
   PubMed Web of Science ®Google Scholar
• Harris C C, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 1993; 329: 1318–1327
   PubMed Web of Science ®Google Scholar
• Nilsen L. L., Maneval D C. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 1998; 5: 52–63
   PubMed Web of Science ®Google Scholar
• Agarwala S S, Ooosterom A V, Petruzalli G, et al. Phase I study of rAd/p53 in patients with advancer head and neck cancer. Proc Am Soc Clin Oncol 1998; 17: 384a
   Google Scholar
• Clayman G L, el-Naggar A K, Lippman S M, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 2221–2232
   PubMed Web of Science ®Google Scholar
• Swisher S G, Roth J A, Neumanitis D D, et al. Adenoviral-mediated p53 gene transfer in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1998; 17: 431a
   Google Scholar
• Timmons T, Burt K, Chema D, et al. Biodistribution of Ad-p53 (INGN 201) in a phase I-II trial of gene therapy for non-small cell lung cancer. Proc Am Soc Clin Oncol 1998; 17: 431a
   Google Scholar
• Venook A P, Bergsland E K, Ring E, et al. Gene therapy of colorectal liver mettastases using a recombinant adenovirus encoding wt p53 (SCH 58500) via hepatic artery infusion. Proc Am Soc Clin Oncol 1998; 17: 431a
   Google Scholar
• Horowitz J, Fritz M A, Swanson S, et al. Transgene expression from the phase I pilot program rAd/p53 (SCH 58500). Proc Am Assoc Cancer Res 1998; 39: 361, (abstract 2460)
   Google Scholar
• Roth J A, Nguyen D, Lawrence D. D., et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2: 985–991
   PubMed Web of Science ®Google Scholar
• Sun Y, Jurgovsky K, Moller P, et al. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 1998; 5: 481–490
   PubMed Web of Science ®Google Scholar
• Lienard D, Lejeune F J, Dummer R, et al. Intratumoral administration of canarypox virus expressing human IL-2 gene (ALVACIL-2) in cancer patients: results of a phase I study. Proc Am Soc Clin Oncol 1998; 17: 430a
   Google Scholar
• Bonnet M C, Dummer R, Lejeune F, et al. Intratumoral administration of canarypox virus expressing human GM-CSF gene (ALVAC-GM-CSF) in cancer patients: results of a phase I study. Proc Am Soc Clin Oncol 1998; 17: 430a
   Google Scholar
• Rubin J, Galanis E, Burch P, et al. Phase I/II trial of immunotherapy by direct gene transfer of the IL-2 DNA/DMRIE/DOPE lipid complex in patients with advanced melanoma, renal cell carcinoma, and sarcoma. Proc Am Soc Clin Oncol 1998; 17: p430a
   Google Scholar
• Hersh E M, Stopeck A T, Klasa R, et al. Allovectin-7 (HLA-B7/ B2m plasmid DNA/lipid complex) therapy in metastatic malignant melanoma, phase II studies. Proc Am Soc Clin Oncol 1998; 17: 430a
   Google Scholar
• Chang J Y, Xia W, Shao R, et al. The tumor suppression activity of ElA in HER-2/neu-overexpressing breast cancer. Oncogene 1997; 14: 561–568
   PubMed Web of Science ®Google Scholar
• Yu D, Matin A, Xia W, et al. Liposome-mediated in vvivo ElA gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene 1995; 11: 1383–1388
   PubMed Web of Science ®Google Scholar
• Murray J L, Yoo G H, Lopez-Berestein L, et al. Phase I trial of intratumoral liposomal-ElA gene therapy in patients with recurrent/refractory breast cancer and head and neck cancer. Proc Am Soc Clin Oncol 1998; 17: 431a
   Google Scholar
• Ueno N T, Hung M C, Weiden P, et al. Phase I ElA gene therapy in patients with advanced breast and ovarian cancers. Proc Am Soc Clin Oncol 1998; 17: 432a
   Google Scholar
• Culver K V, Ram Z, Wallbridge S, et al. In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550–1552
   PubMed Web of Science ®Google Scholar
• Pope I M, Poston G J, Kinsella A R. The role of the bystander effect in suidice gene therapy. Eur J Cancer 1997; 33: 1005–1016
   PubMed Web of Science ®Google Scholar
• Ram Z, Culver K W, Oshiro E M, et al. Therapy of malignant brain tumors by intra tumoral implantation of retroviral vector-producing cells. Nat Med 1997; 3: 1354–1361
   PubMed Web of Science ®Google Scholar
• Sterman D H, Treat J, Litzky L A, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in maligant mesothelioma. Hum Gene Ther 1998; 9: 1083–1092
   PubMed Web of Science ®Google Scholar
• Scardino P T, Adler H L, Herman J R, et al. Herpes simplex virusthymidine kinase mediated gene therapy is safe and active against locally recurrent prostate cancer after irradiation therapy. Proc Am Soc Clin Oncol 1998; 17: 308a
   Google Scholar
• Fisher G A, Sikic B I. Drug resistance in clinical oncology and he-matology. Hematol Oncol Clin North Am 1995; 9: 363–382
   PubMed Web of Science ®Google Scholar
• Brenner M K. Gene transfer to hematopoietic cells. N Engl J Med 1996; 335: 337–339
   PubMed Web of Science ®Google Scholar
• Dunbar C E, Cottler-Fox M, O'Shaughnessy J A, et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3048–3057
   PubMed Web of Science ®Google Scholar
• Hanania E G, Deisseroth A B. Results of MDR-1 vector modification trial indicate that granulocyte-macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci USA 1996; 93: 15346–15351
   PubMed Web of Science ®Google Scholar
• Emmons R V, Doren S, Zujewski J, et al. Retroviral gene transduction of adult peripheral blood or marrow-derived CD34+ cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo. Blood 1997; 89: 4040–4046
   PubMed Web of Science ®Google Scholar
• Hersdorffer C, Ayello J, Ward M, et al. Phase I trail of retroviral-mediated transfer of the human MDR-1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998; 16: 165–172
   PubMed Web of Science ®Google Scholar
• Kirn D, Nemunaitis I, Ganly M, et al. A phase II trial of intratumoral injection with an E lB-deleted adenovirus, ONYX-015. in patients with recurrent, refractory head and neck cancer. Proc Am Soc Clin Oncol 1998; 17: 391a
   Google Scholar
• Nguyen J, Wu P, Hlatky L, et al. Genetic strategies for antiangiogenic therapy of solid tumors. Cancer Gene Ther 1997; 4: S41
   Google Scholar